^
    5d
    Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. (PubMed, Blood Neoplasia)
    Continued studies evaluating JAK inhibitors in patients with T-PLL are warranted. This trial was registered at www.clinicaltrials.gov as #NCT03989466.
    Clinical • P1 data • Journal
    |
    JAK3 (Janus Kinase 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    Campath (alemtuzumab) • itacitinib (INCB039110)
    19d
    Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)
    1m
    Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL (clinicaltrials.gov)
    P2, N=41, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • lenalidomide • Monjuvi (tafasitamab-cxix)
    2ms
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    2ms
    T-PLL: Observatory of Prolymphocytic Leukemia T (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    2ms
    ACE-CL-003: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (clinicaltrials.gov)
    P1, N=69, Completed, Acerta Pharma BV | Trial completion date: Sep 2027 --> Oct 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    2ms
    Asymptomatic T prolymphocytic leukemia: case report and literature review. (PubMed, Einstein (Sao Paulo))
    Standard therapies include alemtuzumab-based regimens and hematopoietic stem cell transplantation, although relapse rates remain high. This case underscores the need to recognize indolent presentations of T-cell prolymphocytic leukemia that may be managed conservatively. Further research is required to identify prognostic markers and optimize therapeutic strategies.
    Review • Journal
    |
    ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ATM mutation
    |
    Campath (alemtuzumab)
    2ms
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclosporin A microemulsion
    4ms
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    4ms
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    4ms
    Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=23, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Jun 2025
    Trial completion • Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Istodax (romidepsin) • fludarabine IV • busulfan
    4ms
    Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • itacitinib (INCB039110)